Anti-Human/Mouse integrin β7 (Clone FIB21) – Purified in vivo GOLD™ Functional Grade

Based on the search results provided, I cannot find any information about a clone called "FIB21" being used in in vivo mouse studies. The search results contain information about several different clones and cell lines, but none specifically match "FIB21."

The search results do contain information about:

• Clone I21: A stable, anchorage-dependent clone derived from a spontaneously transformed mouse fibroblast line (IT22)
• p21-Cre mouse model: Used to study senescent cells in vivo
• Various antibody clones for PD-1 research including clone 29F.1A12

However, none of these appear to be the "FIB21" clone you're asking about. It's possible that:

1. There may be a typographical error in the clone name
2. The specific clone you're interested in may not be covered in these particular search results
3. The clone might be referenced under a different name or designation

If you could provide additional context about the clone FIB21 or verify the exact name, I would be better able to assist you with information about its use in in vivo mouse studies.

The correct storage temperature for sterile packaged clone FIB21, assuming it is a recombinant protein or antibody preparation similar to cell culture sera or ELISA reagents, is typically -20°C for long-term storage, or 4°C for short-term storage up to one month.

• For unused kits or reagents, storage at -20°C preserves stability throughout shelf life. Short-term storage at 4°C is permissible for up to one month if frequently accessed.
• For biological sera (such as FBS), recommended storage is -10°C to -40°C. Liquid (thawed) products can be kept refrigerated at 2–8°C for up to four weeks.

Use only the specific storage recommendation found on the product label or technical datasheet for FIB21, as preservation needs may vary depending on formulation and manufacturer protocols. If handling recombinant proteins or ELISA kits (as with FGF21), always avoid multiple freeze/thaw cycles to maintain bioactivity and prevent precipitation.

Based on the literature, several antibodies and proteins are commonly used in conjunction with or as alternatives to FGF21 (note: I believe you meant FGF21 rather than "FIB21") in research and therapeutic applications.

FGF21 Mimetic Antibodies

Several bispecific antibodies have been developed to mimic FGF21's function by targeting the FGFR1/KLB receptor complex. Clinical trials have investigated BFKB8488A and NGM313, which are agonist antibodies designed to specifically activate the FGFR1/KLB complex. The research antibody bFKB1 serves as a bispecific anti-FGFR1/KLB agonist that acts on mouse receptor complexes, providing a long-acting FGF21 mimetic for preclinical studies.

Modified FGF21 Analogs

Clinical development has focused on modified human FGF21 analogs, particularly LY2405319 and PF05231023, which have demonstrated remarkable metabolic effects in obese and diabetic patients. Researchers have also developed cleavage-resistant FGF21 mutants (such as hFGF21^R^) that are protected from proteolytic degradation by fibroblast activation protein (FAP).

Tumor-Targeting Antibody Platforms

In cancer immunotherapy applications, F8 antibody is frequently used as a targeting platform. This fully human monoclonal antibody specifically recognizes the extra domain A (EDA) of fibronectin, a tumor-related antigen. Similarly, L19 antibody targets the extra domain B (EDB) of fibronectin and has been used in various immunocytokine fusion proteins currently in clinical trials.

Cytokine Fusion Partners

Interleukin-21 (IL-21) represents a major category of proteins used in fusion with targeting antibodies. IL-21-based antibody-cytokine fusion proteins have been developed using the F8 antibody platform to create targeted cancer therapeutics. Other cytokines from the common gamma chain family, including IL-2 and IL-15, serve as comparative controls and alternative therapeutic options in similar applications.

Regulatory Proteins

Fibroblast Activation Protein (FAP) plays a crucial role in FGF21 biology as an enzyme that cleaves and inactivates FGF21, making FAP inhibition a potential therapeutic approach to enhance endogenous FGF21 activity. Dipeptidyl peptidase IV (DPPIV) also demonstrates proteolytic activity against FGF21, though with different cleavage specificity compared to FAP.

These proteins and antibodies represent the major molecular tools used alongside FGF21 in both research and clinical development, spanning applications from metabolic disease treatment to cancer immunotherapy.

Based on the provided search results, clone FIB21 appears to be primarily associated with integrin ?7 antibody research, but the search results contain limited specific information about key findings from FIB21 citations in scientific literature.

Integrin ?7 Research Context

Clone FIB21 is identified as an antibody clone targeting integrin ?7, a 130 kD glycoprotein also known as integrin ?p that belongs to the immunoglobulin superfamily. This antibody is available in various formats including APC, PE, and PerCP/Cyanine 5.5 conjugations for research applications.

Limited Citation Data Available

The search results indicate that there are publications citing FIB21, as evidenced by the notation "Citations ({{item.publications_count}})" in the database entries. However, the specific number of citations and detailed findings from these studies are not provided in the available search results.

Related Research Context

While the search results don't provide specific findings from FIB21 citations, they do include information about related research areas that may be relevant to integrin ?7 studies:

The search results reference metabolic research, particularly involving fibroblast growth factor-21 (FGF-21), which has been extensively studied for its metabolic regulatory effects. However, this appears to be separate from the integrin ?7/FIB21 antibody research.

Research Applications

The FIB21 clone is used in immunological research targeting human and mouse integrin ?7, suggesting its applications likely involve studies of immune cell trafficking, inflammatory responses, and potentially gastrointestinal immunity, as integrin ?7 is known to play important roles in lymphocyte homing to mucosal tissues.

Unfortunately, the search results do not contain sufficient detail about the specific key findings, breakthrough discoveries, or significant contributions from studies that have cited the FIB21 clone. To obtain comprehensive information about FIB21 citation findings, additional literature searches focusing specifically on integrin ?7 research and studies utilizing this particular antibody clone would be necessary.